LEF1 supports metastatic brain colonization by regulating glutathione metabolism and increasing ROS resistance in breast cancer
Raquel Blazquez,Eva Rietkötter,Britta Wenske,Darius Wlochowitz,Daniela Sparrer,Elena Vollmer,Gunnar Müller,Julia Seegerer,Xueni Sun,Katja Dettmer,Alonso Barrantes‐Freer,Lena Stange,Kirsten Utpatel,Annalen Bleckmann,Hannes Treiber,Hanibal Bohnenberger,Christof Lenz,Matthias Schulz,Christian Reimelt,Christina Hackl,Marian Grade,Deram Büyüktas,Laila Siam,Marko Balkenhol,Christine Stadelmann,Dieter Kube,Michael P. Krahn,Martin A. Proescholdt,Markus J. Riemenschneider,Matthias Evert,Peter J. Oefner,Chistoph A. Klein,Uwe K. Hanisch,Claudia Binder,Tobias Pukrop
DOI: https://doi.org/10.1002/ijc.32742
2020-06-01
International Journal of Cancer
Abstract:More than half of all brain metastases show infiltrating rather than displacing growth at the macro‐metastasis/brain parenchyma interface (MMPI), a finding associated with shorter survival. The Lymphoid Enhancer‐binding Factor‐1 (LEF1) is an epithelial‐mesenchymal transition (EMT) transcription factor that is commonly overexpressed in brain‐colonizing cancer cells. Here, we overexpressed LEF1 in an in vivo breast cancer brain colonization model. It shortened survival, albeit without engaging EMT at the MMPI. By differential proteome analysis, we identified a novel function of LEF1 as a regulator of the glutathione (GSH) system, the principal cellular redox buffer. LEF1 overexpression also conferred resistance against therapeutic GSH depletion during brain colonization and improved management of intracellular ROS. We conclude that besides EMT, LEF1 facilitates metastasis by improving the anti‐oxidative capacity of epithelial breast cancer cells, in particular during colonization of the brain parenchyma.This article is protected by copyright. All rights reserved.
oncology